Marc Dunoyer appointed Chief Financial Officer of AstraZeneca
Posted: 31 October 2013 | European Pharmaceutical Review | No comments yet
“Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience…”
AstraZeneca today announced that Marc Dunoyer has been appointed Chief Financial Officer and will join the company Board as an Executive Director. He succeeds Simon Lowth who leaves AstraZeneca today, as previously announced. Marc Dunoyer’s appointment takes effect on 1 November 2013. He will report to Chief Executive Officer, Pascal Soriot and remain a member of the Senior Executive Team.
Marc Dunoyer, currently Executive Vice President, Global Portfolio & Product Strategy, joined AstraZeneca from GlaxoSmithKline in June 2013. Marc qualified as an accountant. His subsequent career in pharmaceuticals has given him extensive experience of the industry including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development.
Pascal Soriot, AstraZeneca’s Chief Executive Officer said: “I’m delighted with Marc’s appointment as CFO. Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience that will be critical in this role in the coming years as we focus on returning AstraZeneca to growth and achieving scientific leadership.”
Leif Johansson, Chairman of the AstraZeneca Board commented: “Marc’s unique combination of global industry knowledge gained in emerging and established markets and strong business and financial experience will enable him to make a significant contribution to the success of the company at senior executive and Board level.”
The appointment of Marc Dunoyer’s successor as Executive Vice President, Global Portfolio & Product Strategy will be the subject of a separate announcement.
No disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority’s Listing Rules in respect of this appointment.
Marc Dunoyer’s base salary will be £680,000 per annum. His annual bonus opportunity will be in the range of 0% – 150% with a target annual bonus of 90% of base salary. His target long-term incentive award will be 200% of base salary per annum. Full details will be published in AstraZeneca’s annual report for 2013. His remuneration will next be reviewed at the end of 2014.
